When it comes to competition, some pay attention to sports. Others will pay their mind to something as grand as the Olympics. Yet still, others will even bring their competitive desires to something as niche as video games. Regardless of where it is held, competition is meant to bring out the best in its competitors, whether it be in sports, knowledge, or what have you. The same is to be implied in the world of marketing, especially in pharmaceutical fields. As of late, there's been some waves being made with CVS and Mylan, and come this February, a former competitor will be rearing its head. Coming this February, Kaleo will be putting its product to the test and allowing 200 million people to have a chance at trying it out for free.
While CVS and Mylan have butted heads with their whole pricing debacle, the Detroit Free Press states that Kaleo will be entering the ring of competition once more by claiming that Auvi-Q, their own product and version of an epinephrine auto-injector, will have a far lower price for consumers with commercial insurance when compared to any of its brand name or generic competitors. Despite CEO Spencer Williamson claiming that many plans will be covering Auvi-Q, he still has not named any.
With competition now running high due to the recent price gouging, Us.pressfrom.com claims that this has not been Mylan's first dance with Kaleo before. In fact, Kaleo's product has been recalled from the market before. Despite EpiPen's dominance in the market, it now shows that the tides of competition will grow with Kaleo's new appearance, thus making it a three-way battle between CVS, Mylan, and Kaleo. Price cuts aside, what makes Kaleo's product different is its easy-to-use tutorial as well as the fact that it will be free to those patients with commercial insurance even if they have a deductable plan. Now, the three companies will be vying for dominance in the companies once more, and competition will prove the victor.
